Peptidomics Strategies to Evaluate Cancer Diagnosis, Prognosis, and Treatment

Overview

Journal Methods Mol Biol

Specialty Molecular Biology

Date 2024 Mar 29

PMID 38549027

Authors

Daniella Figueiredo

Rodrigo G B Cruz

Ana Gabriela Costa Normando

Daniela C Granato

Ariane F Busso-Lopes

Carolina M Carnielli

Tatiane De Rossi

Adriana Franco Paes Leme

Affiliations

Soon will be listed here.

Abstract

Peptides have potential bioactive functions, and the peptidomics landscape has been broadly investigated for various diseases, including cancer. In this chapter, we reviewed the past four years of literature available and selected 16 peer-reviewed publications exploring peptidomics in diagnosis, prognosis, and treatment in cancer research. We highlighted their main aims, mass spectrometry-based peptidomics, multi-omics, data-driven and in silico strategies, functional assays, and clinical applications. Moreover, we underscored several levels of difficulties in translating the peptidomics findings to clinical practice, aiming to learn with the accumulated knowledge and guide upcoming studies. Finally, this review reinforces the peptidomics robustness in discovering potential candidates for monitoring the several stages of cancer disease and therapeutic treatment, leveraging the management of cancer patients in the future.

References

Muller S, Tilakaratne W . Update from the 5th Edition of the World Health Organization Classification of Head and Neck Tumors: Tumours of the Oral Cavity and Mobile Tongue. Head Neck Pathol. 2022; 16(1):54-62. PMC: 9018914. DOI: 10.1007/s12105-021-01402-9. View

Brohl A, Sindiri S, Wei J, Milewski D, Chou H, Song Y . Immuno-transcriptomic profiling of extracranial pediatric solid malignancies. Cell Rep. 2021; 37(8):110047. PMC: 8642810. DOI: 10.1016/j.celrep.2021.110047. View

Reustle A, Di Marco M, Meyerhoff C, Nelde A, Walz J, Winter S . Integrative -omics and HLA-ligandomics analysis to identify novel drug targets for ccRCC immunotherapy. Genome Med. 2020; 12(1):32. PMC: 7106651. DOI: 10.1186/s13073-020-00731-8. View

Wickstrom S, Lovgren T, Volkmar M, Reinhold B, Duke-Cohan J, Hartmann L . Cancer Neoepitopes for Immunotherapy: Discordance Between Tumor-Infiltrating T Cell Reactivity and Tumor MHC Peptidome Display. Front Immunol. 2020; 10:2766. PMC: 6918724. DOI: 10.3389/fimmu.2019.02766. View

Li X, Li J, Zhang B, Gu Y, Li Q, Gu G . Comparative peptidome profiling reveals critical roles for peptides in the pathology of pancreatic cancer. Int J Biochem Cell Biol. 2020; 120:105687. DOI: 10.1016/j.biocel.2020.105687. View

Wang X, Liu G, Sheng N, Zhang M, Pan X, Liu S . Peptidome characterization of ovarian cancer serum and the identification of tumor suppressive peptide ZYX. Ann Transl Med. 2020; 8(15):925. PMC: 7475411. DOI: 10.21037/atm-20-2018. View

Wang L, Wang N, Zhang W, Cheng X, Yan Z, Shao G . Therapeutic peptides: current applications and future directions. Signal Transduct Target Ther. 2022; 7(1):48. PMC: 8844085. DOI: 10.1038/s41392-022-00904-4. View

Karami Fath M, Babakhaniyan K, Zokaei M, Yaghoubian A, Akbari S, Khorsandi M . Anti-cancer peptide-based therapeutic strategies in solid tumors. Cell Mol Biol Lett. 2022; 27(1):33. PMC: 8994312. DOI: 10.1186/s11658-022-00332-w. View

Di Meo A, Pasic M, Yousef G . Proteomics and peptidomics: moving toward precision medicine in urological malignancies. Oncotarget. 2016; 7(32):52460-52474. PMC: 5239567. DOI: 10.18632/oncotarget.8931. View

10.

Duan B, Hu X, Fan M, Xiong X, Han L, Wang Z . RNA-Binding Motif Protein 6 is a Candidate Serum Biomarker for Pancreatic Cancer. Proteomics Clin Appl. 2019; 13(5):e1900048. DOI: 10.1002/prca.201900048. View

11.

Huang Y, Chen F, Zhang L, Lv Q, Yan J, Cui W . MALDI-TOF-MS Analysis in the Discovery and Identification of the Serum Peptide Pattern of Pancreatic Ductal Adenocarcinoma. Lab Med. 2021; 52(6):558-566. DOI: 10.1093/labmed/lmab024. View

12.

de Oliveira T, de Lacerda J, Leite G, Dias M, Mendes M, Kassab P . Label-free peptide quantification coupled with in silico mapping of proteases for identification of potential serum biomarkers in gastric adenocarcinoma patients. Clin Biochem. 2020; 79:61-69. DOI: 10.1016/j.clinbiochem.2020.02.010. View

13.

Shraibman B, Barnea E, Melamed Kadosh D, Haimovich Y, Slobodin G, Rosner I . Identification of Tumor Antigens Among the HLA Peptidomes of Glioblastoma Tumors and Plasma. Mol Cell Proteomics. 2019; 18(6):1255-1268. PMC: 6553928. DOI: 10.1074/mcp.RA119.001524. View

14.

Chakraborty S, Andrieux G, Hasan A, Ahmed M, Hosen M, Rahman T . Harnessing the tissue and plasma lncRNA-peptidome to discover peptide-based cancer biomarkers. Sci Rep. 2019; 9(1):12322. PMC: 6707329. DOI: 10.1038/s41598-019-48774-1. View

15.

Krochmal M, van Kessel K, Zwarthoff E, Belczacka I, Pejchinovski M, Vlahou A . Urinary peptide panel for prognostic assessment of bladder cancer relapse. Sci Rep. 2019; 9(1):7635. PMC: 6529475. DOI: 10.1038/s41598-019-44129-y. View

16.

Frantzi M, van Kessel K, Zwarthoff E, Marquez M, Rava M, Malats N . Development and Validation of Urine-based Peptide Biomarker Panels for Detecting Bladder Cancer in a Multi-center Study. Clin Cancer Res. 2016; 22(16):4077-86. DOI: 10.1158/1078-0432.CCR-15-2715. View

17.

Di Meo A, Batruch I, Brown M, Yang C, Finelli A, Jewett M . Identification of Prognostic Biomarkers in the Urinary Peptidome of the Small Renal Mass. Am J Pathol. 2019; 189(12):2366-2376. DOI: 10.1016/j.ajpath.2019.08.015. View

18.

Neves L, Granato D, Busso-Lopes A, Carnielli C, de Sa Patroni F, De Rossi T . Peptidomics-Driven Strategy Reveals Peptides and Predicted Proteases Associated With Oral Cancer Prognosis. Mol Cell Proteomics. 2021; 20:100004. PMC: 7950089. DOI: 10.1074/mcp.RA120.002227. View

19.

Chong C, Coukos G, Bassani-Sternberg M . Identification of tumor antigens with immunopeptidomics. Nat Biotechnol. 2021; 40(2):175-188. DOI: 10.1038/s41587-021-01038-8. View

20.

Peng J, Wu R . Metal-organic frameworks in proteomics/peptidomics-A review. Anal Chim Acta. 2018; 1027:9-21. DOI: 10.1016/j.aca.2018.04.069. View